-BioNTech*Biotheus Story

BioSpark facility

a vital role in industrial-scale production

"The launch of our Nantong production base marks our evolution from a biopharmaceutical R&D company to a fully intergrated bio manufacturing enterprise. "

"As a key part of our comprehensive antibody drug development chain, the Nantong facility will play a vital role in industrial-scale production, providing strong support for the development and commercialization of PREMIS’s clinical pipeline."

Mr.Xiaolin Liu

Chairman and CEO of Biotheus

Biotheus, a subsidiary of BioNTech, established in 2018, focuses on the R&D and industrialization of innovative biologics for malignant tumors and autoimmune diseases. The company specializes in developing dual-target biologic drugs.